VX-787 - CAS 1629869-44-8
Catalog number: 1629869-44-8
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C20H19F2N5O2
Molecular Weight:
399.40
COA:
Inquire
Targets:
Influenza Virus
Description:
VX-787, a pyrrolopyridine derivative, has been found to be an antiviral agent and is still under Phase II trial against Influenza A virus infection.
Purity:
98%
Appearance:
Powder
Synonyms:
VX-787; VX 787; VX787; JNJ-872; JNJ 872; JNJ872; VRT-0928787; VRT 0928787; VRT0928787;pimodivir; (2S,3S)-3-((5-Fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)bicyclo[2.2.2]octane-2-carboxylic Acid
Storage:
Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).
MSDS:
Inquire
Quality Standard:
In-house standard
Quantity:
Milligram-Grams
InChIKey:
JGPXDNKSIXAZEQ-SBBZOCNPSA-N
InChI:
InChI=1S/C20H19F2N5O2/c21-11-5-12-13(7-24-17(12)23-6-11)18-25-8-14(22)19(27-18)26-16-10-3-1-9(2-4-10)15(16)20(28)29/h5-10,15-16H,1-4H2,(H,23,24)(H,28,29)(H,25,26,27)/t9?,10?,15-,16-/m0/s1
Canonical SMILES:
C1CC2CCC1C(C2NC3=NC(=NC=C3F)C4=CNC5=NC=C(C=C45)F)C(=O)O
Current Developer:
Janssen Pharmaceuticals; Vertex Pharmaceuticals
1.Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.
Byrn RA;Jones SM;Bennett HB;Bral C;Clark MP;Jacobs MD;Kwong AD;Ledeboer MW;Leeman JR;McNeil CF;Murcko MA;Nezami A;Perola E;Rijnbrand R;Saxena K;Tsai AW;Zhou Y;Charifson PS Antimicrob Agents Chemother. 2015 Mar;59(3):1569-82. doi: 10.1128/AAC.04623-14. Epub 2014 Dec 29.
VX-787 is a novel inhibitor of influenza virus replication that blocks the PB2 cap-snatching activity of the influenza viral polymerase complex. Viral genetics and X-ray crystallography studies provide support for the idea that VX-787 occupies the 7-methyl GTP (m(7)GTP) cap-binding site of PB2. VX-787 binds the cap-binding domain of the PB2 subunit with a KD (dissociation constant) of 24 nM as determined by isothermal titration calorimetry (ITC). The cell-based EC50 (the concentration of compound that ensures 50% cell viability of an uninfected control) for VX-787 is 1.6 nM in a cytopathic effect (CPE) assay, with a similar EC50 in a viral RNA replication assay. VX-787 is active against a diverse panel of influenza A virus strains, including H1N1pdm09 and H5N1 strains, as well as strains with reduced susceptibility to neuraminidase inhibitors (NAIs). VX-787 was highly efficacious in both prophylaxis and treatment models of mouse influenza and was superior to the neuraminidase inhibitor, oseltamivir, including in delayed-start-to-treat experiments, with 100% survival at up to 96 h postinfection and partial survival in groups where the initiation of therapy was delayed up to 120 h postinfection.
2.Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study.
Trevejo JM;Asmal M;Vingerhoets J;Polo R;Robertson S;Jiang Y;Kieffer TL;Leopold L Antivir Ther. 2017 Dec 15. doi: 10.3851/IMP3212. [Epub ahead of print]
BACKGROUND: ;Pimodivir (formerly JNJ-63623872) is a novel, non-nucleoside polymerase complex inhibitor with in vitro activity against influenza A virus, including pandemic 2009 H1N1, H7N9, H5N1 strains as well as neuraminidase- and amantadine-resistant strains.;METHODS: ;Randomized, double-blind, placebo-controlled, Phase IIa study. Healthy volunteers (n=104) were inoculated with an influenza A/Wisconsin/67/2005 (H3N2) challenge virus. 72 received pimodivir and 32 placebo. Pimodivir was dosed for 5 days once daily from 24 h after viral inoculation at four dose levels: 100 mg, 400 mg, loading dose 900/600 mg and loading dose 1,200/600 mg.;RESULTS: ;Pimodivir significantly reduced viral shedding (area under the concentration versus time curve [AUC] measured by 50% tissue culture infective dose [TCID;50;] or qRT-PCR) versus placebo as measured by cell culture assay in the pooled analysis (Jonckheere-Terpstra dose-response trend test [P=0.036]). Reductions were observed in viral shedding (AUC, duration and peak measured by grade), influenza-like symptoms (AUC, duration and peak measured by grade) and clinical symptoms (duration and peak measured by grade) for all pimodivir groups versus placebo, significantly so for the 1,200/600 mg group.
3.JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses.
Fu Y;Gaelings L;Söderholm S;Belanov S;Nandania J;Nyman TA;Matikainen S;Anders S;Velagapudi V;Kainov DE Antiviral Res. 2016 Sep;133:23-31. doi: 10.1016/j.antiviral.2016.07.008. Epub 2016 Jul 20.
JNJ-63623872 (formally known as VX-787; referred to here as JNJ872) is an orally bioavailable compound, which is in phase II clinical trials for the treatment of influenza A virus (IAV) infections. Here we show that JNJ872 inhibits at nanomolar concentrations the transcription of viral RNA in IAV-infected human macrophages by targeting a highly conserved site on the cap-snatching domain of influenza polymerase basic 2 protein (PB2). Furthermore, even lower concentrations of JNJ872 protected macrophages from IAV-mediated death when given in combination with 100 nM gemcitabine, which also attenuated transcription and replication of viral RNA. Importantly, treating human macrophages with JNJ872 allowed expression of many immune-related and other genes, involved in antiviral responses, such as indoleamine 2,3-dioxygenase 1 (IDO), and cytosolic 5'-nucleotidase 3A (NT5C3A). Moreover, our targeted metabolomics analysis indicate that treatment with JNJ782 did not interfere with metabolic responses to infection, which further supported our transcriptomics results. Thus, VX-737 alone or in combination with other drugs could be beneficial for treating IAV infected patients, because it would allow the development of antiviral responses and, thereby, protect individuals from current and future infections with closely related IAV strains.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Influenza Virus Products


CAS 3160-91-6 Moroxydine Hydrochloride

Moroxydine Hydrochloride
(CAS: 3160-91-6)

Moroxydine HCl is a synthetic antiviral compound chemically belonging to the series of the heterocyclic biguanidines.

CAS 187227-45-8 Oseltamivir acid

Oseltamivir acid
(CAS: 187227-45-8)

Oseltamivir acid is the active metabolite of oseltamivir. Oseltamivir, also called as GS 4071 or Ro 64-0802, is an antiviral drug that competitively inhibits ne...

CAS 665-66-7 Amantadine Hydrochloride

Amantadine Hydrochloride
(CAS: 665-66-7)

Amantadine Hydrochloride is a NMDA-receptor antagonist acts as an antiviral and an antiparkinsonian drug.

CAS 1041434-82-5 Peramivir Trihydrate

Peramivir Trihydrate
(CAS: 1041434-82-5)

Peramivir Trihydrate is a trihydrate of the anti-infection agent peramivir (RWJ-270201,BCX-1812) which is a transition-state analogue and a potent, specific inf...

CAS 13392-28-4 Rimantadine

Rimantadine
(CAS: 13392-28-4)

Rimantadine, an adamantane derivative, could be an effective antiviral drug and probably prevent influenza virus at some extent.

CAS 139110-80-8 Zanamivir

Zanamivir
(CAS: 139110-80-8)

Zanamivir is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A virus and influenza B virus.

CEF6

CEF6, one of the the CEF control peptides, is a 9-aa-long peptide corresponding to aa 418-426 of the influenza A virus (H1N1) nucleocapsid protein.

CAS 131707-23-8 Arbidol Hydrochloride

Arbidol Hydrochloride
(CAS: 131707-23-8)

Arbidol HCl is an antiviral treatment for influenza infection.

Chemical Structure

CAS 1629869-44-8 VX-787

Quick Inquiry

Verification code

Featured Items